Clinical Resource Use in Patients Undergoing Intradetrusor Abotulinum Toxin A Injections for Neurogenic Compared to Non-Neurogenic Indications-The Potential for Compensation Inequities for Urologic and Urogynecologic Practices.

When comparing a neurogenic lower urinary tract dysfunction to an overactive bladder population undergoing intradetrusor BoNT-A injections, current procedural billing codes do not reflect the substantial differences in auxiliary staff requirements or room occupancy times.

The absence of nuanced reimbursement mechanisms may foster avoidance of resource-intensive patient populations and their medical access.

Our findings underscore the potential need to consider implementing novel reimbursement strategies to ensure equitable access to care.